TargeGen
San Diego
About TargeGen
TargeGen, Inc., a vascular biology-focused biopharmaceutical company, discovers and develops small molecule kinase inhibitors that target vascular leakage (edema), vascular proliferation (angiogenesis), and inflammation. The company offers its products for the treatment of human diseases, such as heart attack, cancer, and eye diseases; vascular leakage, edema, and the unwanted growth of new blood vessels; pleural effusions, arthritis, pulmonary edema, transplant ischemia, ARDS, brain inflammation, hypovolemia (acute blood loss) CNS disorders, and other serious medical conditions. It serves macular degeneration, diabetic macular edema, and diabetic retinopathy markets. The company was founded in 2002 and is based in San Diego, California. It was acquired by [Sanofi Aventis](/organization/sanofi-aventis-2) in 2010.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $113.7M
- Funding stage: M&A
- Last round: Debt Financing (Sep 2009)
- Website: targegen.com
- Phone: +1 (858)678-0760
Industries & Categories
Biopharma, Biotechnology, Health Care
Social Profiles
Canonical: https://fsome.com/organization/targegen-2421116 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.